Evidence map›Paper›PMID 39211473›Full record

ArticleRSC chemical biology2024

Peptide dendrimers transfecting CRISPR/Cas9 plasmid DNA: optimization and mechanism.

Susanna Zamolo, Elena Zakharova, Lise Boursinhac, Florian Hollfelder, Tamis Darbre, Jean-Louis Reymond

Abstract read
In one paragraph

Article in RSC chemical biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Susanna ZamoloDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern Freiestrasse 3 3012 Bern Switzerland tamis.darbre@unibe.ch jean-louis.reymond@unibe.ch.
Elena ZakharovaDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern Freiestrasse 3 3012 Bern Switzerland tamis.darbre@unibe.ch jean-louis.reymond@unibe.ch.
Lise BoursinhacDepartment of Biochemistry, University of Cambridge 80 Tennis Court Road Cambridge CB2 1GA UK.
Florian HollfelderDepartment of Biochemistry, University of Cambridge 80 Tennis Court Road Cambridge CB2 1GA UK.ORCID https://orcid.org/0000-0002-1367-6312
Tamis DarbreDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern Freiestrasse 3 3012 Bern Switzerland tamis.darbre@unibe.ch jean-louis.reymond@unibe.ch.
Jean-Louis ReymondDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern Freiestrasse 3 3012 Bern Switzerland tamis.darbre@unibe.ch jean-louis.reymond@unibe.ch.ORCID https://orcid.org/0000-0003-2724-2942

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene editing by CRISPR/Cas9 offers great therapeutic opportunities but requires delivering large plasmid DNA (pDNA) into cells, a task for which transfection reagents are better suited than viral vectors. Here we performed a structure-activity relationship study of Z22, a d-enantiomeric, arginine containing, lipidated peptide dendrimer developed for pDNA transfection of a CRISPR/Cas9 plasmid co-expressing GFP. While all dendrimer analogs tested bound pDNA strongly and internalized their cargo into cells, d-chirality proved essential for transfection by avoiding proteolysis of the dendrimer structure required for endosome escape and possibly crossing of the nuclear envelope. Furthermore, a cysteine residue at the core of Z22 proved non-essential and was removed to yield the more active analog Z34. This dendrimer shows >83% GFP transfection efficiency in HEK cells with no detrimental effect on cell viability and promotes functional CRISPR/Cas9 mediated gene editing. It is accessible by solid-phase peptide synthesis and therefore attractive for further development.

Identifiers

PMID39211473
PMCPMC11352961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.